Proliferating cell nuclear antigen (PCNA), p53 and MDM2 expression in Hodgkins disease

• Published in: São Paulo medical journal Vol. 125; no. 2; pp. 77 - 84
• Main Authors: Pinheiro, Gevina Silva, Silva, Maria Regina Régis, Rodrigues, Celso Arrais, Kerbauy, José, de Oliveira, José Salvador Rodrigues
• Format: Journal Article
• Language: English
• Published: Brazil Associação Paulista de Medicina - APM 01-03-2007; Associação Paulista de Medicina
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Child; Epidemiologic Methods; Female; Hodgkin disease; Hodgkin Disease - metabolism; Hodgkin Disease - pathology; Humans; Immunohistochemistry; Lymphocytes - pathology; Male; MEDICINE, GENERAL & INTERNAL; Middle Aged; p53 genes; Prognosis; Proliferating cell nuclear antigen; Proliferating Cell Nuclear Antigen - analysis; Proto-oncogene proteins c-mdm2; Proto-Oncogene Proteins c-mdm2 - analysis; Reed-Sternberg Cells - chemistry; Tumor Suppressor Protein p53 - analysis; Immunohistochemistry; Genes p53; Proto-oncogene proteins c-mdm2; Proteínas proto-oncogênicas c-mdm2; Doença de Hodgkin; Proliferating cell nuclear antigen; Imunohistoquímica; Hodgkin disease; Antígeno nuclear de célula em proliferação; p53 genes
• ISSN: 1516-3180; 1806-9460; 1516-3180
• DOI: 10.1590/s1516-31802007000200003

Tumor cells in Hodgkins disease (HD) express cell proliferation markers that are evaluated according to the oncogenes involved or the expression of their proteins. Correlations between the protein expression grade and clinical data are now important for disease prognosis.
This was a retrospective analysis on proliferating cell nuclear antigen (PCNA), p53 and MDM2 (murine double minute-2) expression using immunohistochemistry, on formalin-fixed, paraffin-embedded tissues from diagnostic biopsies on 51 patients with HD. The study was conducted at the Division of Hematology and Transfusion Medicine, Hospital São Paulo, Universidade Federal de São Paulo.
Antigen expression was evaluated as the proportions of positive Hodgkin and Reed-Sternberg (HRS) cells and reactive lymphocytes (L), which were compared using Spearman correlation coefficients. The Friedman test was used for comparisons between the markers. The Pearson test was used to investigate associations between marker expression and clinical and laboratory parameters, marrow involvement, complete remission (CR) and overall survival (OS) rates.
There was overexpression of antigen proteins in HRS, in relation to L (p < 0.001). In HRS, MDM2 was higher than p53 and PCNA (p < 0.003), while the latter two were equivalent. In L, p53 was lower than MDM2 and PCNA (p < 0.001), while the latter two were equivalent. There was no relationship between protein expression and clinical and laboratory variables or outcome.
PCNA, p53 and MDM2 are tumor markers for HD, but showed no clinical or prognostic significance in our analysis.